Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2026)

Inhibikase Therapeutics (IKT) has 6 years of Non-Current Assets data on file, last reported at $1.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 891.52% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 398.23% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 637.27% from the prior year.
• Non-Current Assets for Q1 2026 stood at $1.2 million, up from $1.1 million in the prior quarter.
• Over the last five years, Non-Current Assets for IKT reached as high as $1.2 million in Q1 2026 and fell as low as $43089.0 in Q2 2022.
• Historically, Non-Current Assets has averaged $439413.5 across 5 years, with a median of $312814.5 in 2023.
• Across the five-year window, Non-Current Assets sank 73.84% in 2025 and soared 891.52% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $565175.0 in 2022, then tumbled by 47.7% to $295599.0 in 2023, then slumped by 49.75% to $148537.0 in 2024, then soared by 637.27% to $1.1 million in 2025, then grew by 5.54% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $1.2 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.